Medlive Technology Co (HKSE:02192) Debt-to-EBITDA : 0.03 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Medlive Technology Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Medlive Technology Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$5.0 Mil. Medlive Technology Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$4.0 Mil. Medlive Technology Co's annualized EBITDA for the quarter that ended in Dec. 2023 was HK$340.6 Mil. Medlive Technology Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.03.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Medlive Technology Co's Debt-to-EBITDA or its related term are showing as below:

HKSE:02192' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.03 Med: 0.11 Max: 0.35
Current: 0.03

During the past 6 years, the highest Debt-to-EBITDA Ratio of Medlive Technology Co was 0.35. The lowest was 0.03. And the median was 0.11.

HKSE:02192's Debt-to-EBITDA is ranked better than
98.67% of 75 companies
in the Medical Distribution industry
Industry Median: 2 vs HKSE:02192: 0.03

Medlive Technology Co Debt-to-EBITDA Historical Data

The historical data trend for Medlive Technology Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medlive Technology Co Debt-to-EBITDA Chart

Medlive Technology Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

0.11

0.17

0.08

0.03

Medlive Technology Co Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial					0.18	0.18	0.05	0.04	0.03

Competitive Comparison of Medlive Technology Co's Debt-to-EBITDA

For the Medical Distribution subindustry, Medlive Technology Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medlive Technology Co's Debt-to-EBITDA Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Medlive Technology Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Medlive Technology Co's Debt-to-EBITDA falls into.

Medlive Technology Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Medlive Technology Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(4.976	+	3.985)	/	287.515
	=	0.03

Medlive Technology Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(4.976	+	3.985)	/	340.566
	=	0.03

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

Medlive Technology Co (HKSE:02192) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Medlive Technology Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Medlive Technology Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Medlive Technology Co (HKSE:02192) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Medlive Technology Co Ltd (HKSE:02192) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1 Baijialou Chaoyang North Road, E1 Red Manor International Bonded Innovation Park, Chaoyang District, Beijing, CHN

Website

https://www.medlive.cn

Medlive is a digital healthcare marketing company that produces customized content for pharmaceutical and medical device firms to specifically target physicians through different promotional channels. The company uses in-house and third-party content teams to produce advertising for its clients by profiling the user preferences of the physicians on the platform who drive procurement and prescription decisions. Its platform also provides medical content consisting of third-party research, informal discussions, and medical news articles. The company also operates a minor internet hospital and SaaS solution that help with medical conferences and clinical research. M3, Japan's leading digital healthcare marketing company owns 38.8% of Medlive through a joint venture.

Medlive Technology Co (HKSE:02192) Headlines

No Headlines